Australian Research Centre in Sex, Health and Society at La Trobe University, December 2022 A major national survey of Australians living with HIV has revealed more than 70 per cent of people living with HIV report their health-related quality of life to be good. This is very close to the target set in the current National HIV Strategy of 75 per cent of people living with HIV reporting good...
MPX – Monkeypox – Your Questions Answered (video) Thorne Harbour Health, 26 Aug, 2022 Thorne Harbour Health’s Cal Hawk is joined by Dr Vincent Cornelisse to unpack the latest information we have about the current global outbreak of the monkeypox virus (MPXV) including what our communities can do now to reduce their risk. Vincent is a specialist in sexual health medicine and...
nam/aidsmap, 14 April 2022 Perceived irrelevance, lack of awareness, problems with access, side effects, negative social impacts, and concerns about lack of STI protection, effectiveness and adherence are the most common reasons for not using PrEP among gay and bisexual men in Australia. This is according to a study recently published in the journal Behavioral Medicine which analysed reasons for...
Anwernekenhe National HIV Alliance (ANA) and ‘Australian Federation of AIDS Organisations (AFAO), June 2021 The Anwernekenhe National HIV Alliance (ANA) and AFAO are very excited to bring you these new digital factsheets for Aboriginal and Torres Strait Islander communities on PrEP, PEP, treatment as prevention, and HIV testing. Representatives from ANA and our other member organisations...
nam/aidsmap, 7 September 2020 A study in which 24 trans women and 24 trans men who were taking gender-affirming hormone therapy were directly observed to take a daily dose of the standard formulation of the HIV prevention medication PrEP found that the levels of the two PrEP drugs tenofovir and emtricitabine were similar to the levels seen in similar cis men and women, and were all above levels...
July/August 2020 The Therapeutic Goods Administration (TGA) advises: Consumers and health professionals are advised that there is a shortage of oral contraceptive pills containing the combination ethinylestradiol and norethisterone. The affected products are: Brevinor – norethisterone 0.5 mg and ethinylestradiol 35 micrograms Norimin – norethisterone 0.5 mg and ethinylestradiol 35...